StonvexLoading…
StonvexStonvexStonvexCore line items from PCRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $177.38M | $726.41M | $529.54M | $350.02M |
Operating Income | $6.90M | $19.19M | $16.85M | $10.49M |
Net Income | $2.92M | $7.03M | $5.40M | $-35.00K |
EPS (Diluted) | $0.07 | $0.16 | $0.12 | $0.00 |
Total Assets | $1.21B | $1.26B | $1.30B | $1.54B |
Total Liabilities | $554.64M | $571.81M | $570.36M | $779.50M |
Cash & Equivalents | $144.31M | $158.54M | $147.59M | $300.48M |
Free Cash Flow OCF − CapEx | $22.96M | $136.66M | $93.19M | $36.23M |
Shares Outstanding | 39.31M | 41.12M | 42.97M | 44.90M |